RSH (ASX) Ann: Half Yearly Report and Accounts

Originally posted by Richney ↑

This post perfectly sums up your complete lack of knowledge and understanding of the diagnosis and management of asthma and other chronic respiratory disease. The fact that you compare an asthma attack to a panic attack is laughable and shows how little you understand about asthma.

You say that monitoring wheeze means nothing…guess what a doctor does when my son goes in for his 12 month asthma review, they measure and assess his wheezing! And guess what’s one of the first tests a doctor does when diagnosing asthma….you guessed it, they listen for wheezing. This is because wheezing is a primary symptom of a diagnosed asthmatic and a very important indicator as to state and level of construction of a patients airways (which of left unchecked can exacerbate into a full blow asthma attack).

So I guess you can say that assessing and measuring wheeze as the primary symptom of asthma (and other chronic respiratory diseases) I diagnosed asthmatics is incredibly important…so important in fact that it can save lives!

Once again I have had to correct your ever increasing number of mistakes and your complete lack of knowledge. This is important for everyone to see as your posts are both misguided and at worst dangerous. So you can keep banging on about how wheeze means nothing and it does not mean you have asthma or an asthma attack. This may be the case if you are not a diagnosed asthmatic, just like coughing doesn’t mean you have pneumonia, cancer, Etc unless you are diagnosed with cancer or pneumonia. Symptoms are indicators of that state of a patients condition who has been diagnosed with that condition so they can actively manage their treatment and medication usage before they end up in an emergency room or dead.

RSH’s technology provides an objective monitoring and management system that gives data on the state of an asthmatic primary symptom in real-time via a measurement of the % of wheeze in a number of breath cycles (inhalation & exhalation) over a short time period (20-30secs). The higher the % reading the higher the wheezing which means the patient airways are constricting. This constricting of the airways, of left unchecked and not addressed with medication can manifest into a catastrophic constriction resulting in an attack or major exacerbation. This does not happen in a few minutes and can happen over a number of hours or days. This is the critical importance of a having a monitoring and management tool like wheezo to be able to regularly measure a patients breathing and implement treatment BEFORE the wheezing and airway constriction is beyond the point of treatment and only can be dealt with in the ER.

Wheezo allows proactive management of asthma symptoms and promotes preventative healthcare….it’s too late once you are in the ER because by then you already know you are having an attack (which could have been hours or days after the diagnosed patient started wheezing).

So I reinforce again, monitoring and managing wheeze in a diagnosed asthmatic is incredibly important, so important in fact that doctors/ specialist do it and it is the primary focus of an asthmatics asthma plan….”is the patient wheezing/measure the patients wheeze”.

Finally, RSH’s other product they have complements Wheezp which is the daytime monitoring and management platform because it is primarily used as a nighttime/overnight system to monitor nocturnal wheeze. Why is this important, because over 75% of all deaths from asthma occur at night! There is currently no other technology in the market that can monitor wheezing overnight in the home and the RSH’s system will be able to do this. So the 2 products that RSH has in its portfolio when combined provide a complete end-to-end objective real-time monitoring System that measures the primary symptom of diagnosed asthmatics, wheezing and allows patients and carers the ability to implement proactive treatment and mediation application for more preventative healthcare and better health outcomes.

SpIrometry tests lung function and is used primarily for diagnosis of chronic respiratory disease and whilst there is portable Spirometry option, it is very rarely used in ongoing monitoring and management and rarely used by doctors in asthma reviews (they use stethoscope and Spirometry too expensive and time consuming for ongoing monitoring and management).

Measuring wheeze day and night in a diagnosed asthmatic is incredibly important as it is a excellent indicator of airway constriction and severity of symptom of a number of hours or days. If measured objectively and regularly it can keep asthmatics out of hospital and alive. It’s the first thing doctors do so it must be important!

Please do not listen to Alcrap when he says wheezing doesn’t mean you are having a asthma attack or even asthma as in a a diagnosed asthmatic it is the primary symptom and when measured objectively in real-time using Wheezo, it will indicator whether a patients airway is constricting (the higher -% wheeze the more dangerous) or not. He is completely wrong.

Expand

such a great synopsis @Richney - thank you for your valuable time with putting together a very clear and thorough synopsis of all the key points - much appreciated )

No.	Vol.	Price($)
2	535000	7.3¢

No.

Vol.

Price($)

535000

7.3¢

Price($)	Vol.	No.
7.4¢	23529	1

Price($)

Vol.

No.

7.4¢

23529

No.	Vol.	Price($)
2	535000	0.073
1	200000	0.072
1	300000	0.071
1	20000	0.070
1	99997	0.065

No.

Vol.

Price($)

535000

0.073

200000

0.072

300000

0.071

20000

0.070

99997

0.065

Price($)	Vol.	No.
0.074	23529	1
0.075	53371	2
0.076	36475	1
0.079	100000	1
0.080	60000	1

Price($)

Vol.

No.

0.074

23529

0.075

53371

0.076

36475

0.079

100000

0.080

60000

(20min delay)
Last 7.4¢		Change -0.002(2.63%)		Mkt cap ! $95.53M

Open	High	Low	Value	Volume
7.8¢	7.8¢	7.4¢	$99.92K	1.304M

Ann: Half Yearly Report and Accounts, page-21

Talga Group wins key permit for flagship graphite mine in Sweden

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

Macro, Norden set up transport solutions initiative for West Pilbara

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

Nanoveu surges 10% after benchmark testing for new AI chip begins

Sierra Nevada raises $2M for silver exploration at Blackhawk

What's causing the cost-of-living crisis, and how to navigate it

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Half Yearly Report and Accounts, page-21

Top Stories

Talga Group wins key permit for flagship graphite mine in Sweden

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

Macro, Norden set up transport solutions initiative for West Pilbara

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

Nanoveu surges 10% after benchmark testing for new AI chip begins

Sierra Nevada raises $2M for silver exploration at Blackhawk

What's causing the cost-of-living crisis, and how to navigate it

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News